Generic Sitavig Availability
Last updated on Apr 10, 2024.
Sitavig is a brand name of acyclovir, approved by the FDA in the following formulation(s):
SITAVIG (acyclovir - tablet;buccal)
-
Manufacturer: LNHC
Approval date: April 12, 2013
Strength(s): 50MG [RLD]
Has a generic version of Sitavig been approved?
No. There is currently no therapeutically equivalent version of Sitavig available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sitavig. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Mucoadhesive buccal tablets for the treatment of orofacial herpes
Patent 8,592,434
Issued: November 26, 2013
Inventor(s): Attali Pierre & Costantini Dominique & Lemarchand Caroline
Assignee(s): BioAlliance Pharma SAThe present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.
Patent expiration dates:
- June 16, 2030✓✓
- June 16, 2030
-
Mucosal bioadhesive slow release carrier for delivering active principles
Patent 8,747,896
Issued: June 10, 2014
Inventor(s): Costantini Dominique & Lemarchand Caroline
Assignee(s): BioAlliance PharmaA mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
Patent expiration dates:
- June 3, 2027✓✓
- June 3, 2027
-
Mucosal bioadhesive slow release carrier for delivering active principles
Patent 8,791,127
Issued: July 29, 2014
Inventor(s): Costantini Dominique & Lemarchand Caroline
Assignee(s): BioAlliance PharmaA mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
Patent expiration dates:
- March 23, 2027✓✓
- March 23, 2027
More about Sitavig (acyclovir)
- Check interactions
- Compare alternatives
- Reviews (12)
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: purine nucleosides
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.